|
||
 |
|
|
主な論文20編
1. Yamamoto R, Kao
LC, McKnight CE, Strauss JF. Cloning and sequence of cDNA for human placental
cytokeratin 8. Regulation of the mRNA in trophoblastic cells by cAMP. Mol
Endocrinol 1990;4:370-4. 2. Yamamoto R,
Sakamoto T, Nishi S, Sakai M, Morinaga T, Tamaoki T. Expression of human
alpha-fetoprotein in yeast. Life Sci 1990;46:1679-86. 3. Yamamoto R,
Kallen CB, Babalola GO, Rennert H, Billheimer JT, Strauss JF. Cloning and expression of a cDNA encoding
human sterol carrier protein 2. Proc Natl Acad Sci USA 1991;88:463-7. 4. Yamamoto R, Ishikura H, Azuma M, et al. Alpha-fetoprotein production by a hepatoid adenocarcinoma
of the uterus. J Clin Pathol 1996;49:420-22. 5. Yamamoto R,
Taketa K, Ebina Y, et al. Lectin affinity electrophoresis in a yolk sac
tumour in the vagina with yolk sac tumour-type glycoform of alpha fetoprotein.
J Clin Pathol 1997;50:856-8. 6. Yamamoto R, Wakui Y, Taketa
K, et al. A study on the lectin reactivity of alpha-fetoprotein produced
by hepatoid adenocarcinomas and yolk sac tumors. Tumour Biol 1999;20:212-7. 7. Yamamoto R, Fujita M, Kuwabara M, et al.
Malignant Brenner tumors of the ovary and tumor markers. Jpn J Clin Oncol
1999;29:308-13. 8. Yamamoto R, Okamoto K, Ebina
Y, Shirato H, Sakuragi N, Fujimoto S. Prevention of vaginal shortening following
radical hysterectomy. Br J Obstet Gynaecol 2000;107:841-5. 9. Yamamoto R, Saitoh T, Kusaka T, et al.
Prevention of lymphocyst formation following systematic lymphadenectomy. Jpn J
Clin Oncol 2000;30: 397-400. 10. Yamamoto R, Azuma M, Wakui
Y, et al. Alpha-fetoprotein microheterogeneity. a potential biochemical
marker for Down’s syndrome. Clin Chim Acta 2001;304: 137-41. 11. Yamamoto R, Azuma M, Hoshi N, Kishida T,
Satomura S, Fujimoto S. Lens culinaris agglutinin-reactive
alpha-fetoprotein, an alternative variant to alpha-fetoprotein in prenatal
screening for Down’s syndrome. Hum Reprod 2001;16:2438-44. 12. Yamamoto R, Azuma M, Kishida T, Yamada H, Satomura S, Fujimoto S. Total
alpha-fetoprotein and Lens culinaris agglutinin-reactive alpha-fetoprotein
in fetal chromosomal abnormalities. Br J Obstet.Gynaecol
2001;108:1154-8. 13. Yamamoto R, Okamoto K, Todo Y, et al. A study of risk
factors for ovarian metastases in stages IB - IIIB cervical carcinoma and
analysis of ovarian function after a transposition. Gynecol Oncol 2001;82:
312-6. 14. Yamamoto R, Sakuragi N, Shirato H,
Shimizu M, Fujimoto S. Radiotherapy with concurrent chemotherapy for vulvar
adenocarcinoma associated with extramammary Paget’s disease. Gynecol Oncol
2001;80:267-71. 15. Yamamoto R, Minobe S, Kaneuchi M, et
al. A phase I/II and pharmacokinetic study of carboplatin and paclitaxel in
Japanese patients with epitherial ovarian cancer. Jpn J Clin Oncol
2002;32:128-34. 16. Yamamoto R, Kaneuchi M, Nishiya M, et
al. Clinical trial and pharmacokinetic study of combination paclitaxel and
carboplatin in patients with epithelial ovarian cancer. Cancer Chemo Pharma
2002;50:137-42. 17. Yamamoto R, Ohkouchi T, Wakui Y, et al. A study on the
microheterogeneity of alpha-fetoproteins produced by yolk sac and germ cell
tumors. Acta Obstet Gynecol Scand 2003;82:876-82. 18. Yamamoto R, Minobe S, Ebina Y, et al.
Prenatal trisomy 21 screening using the Lens culinaris
agglutinin-reactive alpha-fetoprotein ratio. Congenit Anom (Kyoto) 2004;44:87-92. 19. Yamamoto R, Yonesaka A, Nishioka S, et
al. High dose three- dimensional
conformal boost (3DCB) using an orthogonal diagnostic X-ray set-up for patients
with gynecological malignancy: a new application of real-time tumor-tracking
system. Radiother Oncol 2004;73;219-22. |
||||||||||||||||||||||||||
